Celsion Corporation Share Price Nasdaq
Stocks
US15117N3052
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 06-23 | IMUNON Inc. Continues Phase 3 OVATION 3 Clinical Trial Of IMNN-001 In Combination With Standard Of Care Chemotherapy | CI |
| 06-23 | Imunon's Phase 3 Ovarian Cancer Trial Cleared to Continue | MT |
| Market Cap | 7.52M 6.6M 6.08M 5.69M 10.67M 710M 10.89M 73.07M 28.27M 351M 28.24M 27.63M 1.22B | P/E 2026 * |
-0.57x | P/E 2027 * | -0.79x |
|---|---|---|---|---|---|
| Enterprise Value | 7.52M 6.6M 6.08M 5.69M 10.67M 710M 10.89M 73.07M 28.27M 351M 28.24M 27.63M 1.22B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
98.4% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Celsion Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
Stacy Lindborg
CEO | Chief Executive Officer | 56 | 12/05/2024 |
Jeffrey Church
DFI | Director of Finance/CFO | 69 | 07/07/2010 |
Douglas Faller
CTO | Chief Tech/Sci/R&D Officer | 73 | 17/02/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Tardugno
CHM | Chairman | 75 | 06/10/2014 |
Frederick Fritz
BRD | Director/Board Member | 75 | 07/07/2011 |
Donald Braun
BRD | Director/Board Member | 76 | 14/12/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.33% | +1.37% | +63.66% | +126.38% | 55.63B | |
| +0.82% | +15.05% | +79.52% | +85.53% | 52.25B | |
| +1.36% | +0.36% | -14.52% | -13.83% | 23.07B | |
| -1.04% | +7.91% | +3.91% | +417.68% | 22.41B | |
| -0.18% | +7.20% | +31.37% | -13.62% | 17.32B | |
| -1.10% | +4.00% | +29.97% | -33.36% | 15.94B | |
| +2.89% | +5.51% | +25.42% | +186.30% | 13.77B | |
| -3.35% | +8.96% | +134.32% | +289.59% | 13.47B | |
| +1.31% | +0.53% | +27.83% | - | 12.43B | |
| Average | +0.12% | +4.78% | +42.39% | +130.58% | 25.14B | |
| Weighted average by Cap. | +0.26% | +5.13% | +48.50% | +122.68% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -16.41M -14.39M -13.26M -12.41M -23.28M -1.55B -23.76M -159M -61.67M -765M -61.61M -60.27M -2.65B | -23.33M -20.45M -18.85M -17.65M -33.1M -2.2B -33.79M -227M -87.68M -1.09B -87.59M -85.68M -3.77B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
